The F1F3 recombinant chimera induced higher vaccine efficacy than its independent F1 and F3 components against Leishmania (L.) infantum chagasi mice infection

IntroductionVisceral leishmaniasis (VL) is a severe human vector-borne CD4-immunosuppressive disease that can be lethal if untreated soon after symptoms arise. No vaccine is available against human VL, and its chemotherapy is highly toxic and requires hospitalization. VL patients show substantially...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniele Crespo Gomes, Maria Paula Fonseca-Ribeiro, Marcus Vinicius Alves-Silva, Clarisa B. Palatnik-de-Sousa
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1598755/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849427098164264960
author Daniele Crespo Gomes
Maria Paula Fonseca-Ribeiro
Marcus Vinicius Alves-Silva
Clarisa B. Palatnik-de-Sousa
author_facet Daniele Crespo Gomes
Maria Paula Fonseca-Ribeiro
Marcus Vinicius Alves-Silva
Clarisa B. Palatnik-de-Sousa
author_sort Daniele Crespo Gomes
collection DOAJ
description IntroductionVisceral leishmaniasis (VL) is a severe human vector-borne CD4-immunosuppressive disease that can be lethal if untreated soon after symptoms arise. No vaccine is available against human VL, and its chemotherapy is highly toxic and requires hospitalization. VL patients show substantially decreased CD4+ total and Leishmania-specific CD4+ T cell counts. Leishmania (L.) donovani nucleoside hydrolase (NH36) is a DNA metabolism enzyme and a conserved marker of the Leishmania genus. It has been considered, among other Leishmania antigens, a vaccine candidate. In mice vaccinated with NH36, protection against VL is mediated by a CD4+ T cell response to the NH36 C-terminal domain (F3), and against cutaneous leishmaniasis (CL), by a CD4+ response against F3 and a CD8+ response against the NH36 N-terminal (F1). Vaccination with a recombinant chimera containing the F1 and F3 domains expressed in tandem (F1F3) protected mice against the heterologous CL infection by L. (L.) amazonensis and L. (V.) braziliensis. MethodsIn this investigation, BALB/c mice were immunized with either F1, F3, a mixture of both, or with the F1F3 chimera, plus saponin and challenged with amastigotes of L. (L.) infantum chagasi, the agent of VL in America. ResultsBefore and after infection, the F1F3 chimera and the F3 vaccines promoted the highest IgA, IgM, IgG, IgG1, IgG2a, IgG2b, and IgG3 antibody responses. The F1F3 chimera promoted the strongest intradermal response against the leishmanial antigen, the highest body weight gain, and the most potent reduction of the spleen and liver relative weights. In addition, the F1F3 chimera vaccine increased the secretion of IFN-γ, and, together with the F3 vaccine, the secretion of TNF-α by splenocytes. The F1F3 chimera and the F1 vaccine also promoted the strongest secretion of IL-10, which was very low in mice immunized with F3. Thus, the IFN-γ/IL-10 and TNF-α/IL-10 ratios, characteristic of a Th1 response, were increased in mice vaccinated with F3. The F1F3 chimera and the F3 vaccine reduced the parasite load in the liver.DiscussionThe F1F3 chimera, as described for the heterologous CL infections, also optimizes protection against the homologous visceral leishmaniasis infection by L. (L.) infantum chagasi, by a Th1 contribution from the F3 peptide and a regulatory response from the F1 peptide. Expression of the F1 and F3 domains in tandem induced higher efficacy than the simple mixture of the F1 and F3 domains.
format Article
id doaj-art-dc79ec75c37249d4ad826f7e717ebd00
institution Kabale University
issn 1664-3224
language English
publishDate 2025-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-dc79ec75c37249d4ad826f7e717ebd002025-08-20T03:29:07ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-07-011610.3389/fimmu.2025.15987551598755The F1F3 recombinant chimera induced higher vaccine efficacy than its independent F1 and F3 components against Leishmania (L.) infantum chagasi mice infectionDaniele Crespo GomesMaria Paula Fonseca-RibeiroMarcus Vinicius Alves-SilvaClarisa B. Palatnik-de-SousaIntroductionVisceral leishmaniasis (VL) is a severe human vector-borne CD4-immunosuppressive disease that can be lethal if untreated soon after symptoms arise. No vaccine is available against human VL, and its chemotherapy is highly toxic and requires hospitalization. VL patients show substantially decreased CD4+ total and Leishmania-specific CD4+ T cell counts. Leishmania (L.) donovani nucleoside hydrolase (NH36) is a DNA metabolism enzyme and a conserved marker of the Leishmania genus. It has been considered, among other Leishmania antigens, a vaccine candidate. In mice vaccinated with NH36, protection against VL is mediated by a CD4+ T cell response to the NH36 C-terminal domain (F3), and against cutaneous leishmaniasis (CL), by a CD4+ response against F3 and a CD8+ response against the NH36 N-terminal (F1). Vaccination with a recombinant chimera containing the F1 and F3 domains expressed in tandem (F1F3) protected mice against the heterologous CL infection by L. (L.) amazonensis and L. (V.) braziliensis. MethodsIn this investigation, BALB/c mice were immunized with either F1, F3, a mixture of both, or with the F1F3 chimera, plus saponin and challenged with amastigotes of L. (L.) infantum chagasi, the agent of VL in America. ResultsBefore and after infection, the F1F3 chimera and the F3 vaccines promoted the highest IgA, IgM, IgG, IgG1, IgG2a, IgG2b, and IgG3 antibody responses. The F1F3 chimera promoted the strongest intradermal response against the leishmanial antigen, the highest body weight gain, and the most potent reduction of the spleen and liver relative weights. In addition, the F1F3 chimera vaccine increased the secretion of IFN-γ, and, together with the F3 vaccine, the secretion of TNF-α by splenocytes. The F1F3 chimera and the F1 vaccine also promoted the strongest secretion of IL-10, which was very low in mice immunized with F3. Thus, the IFN-γ/IL-10 and TNF-α/IL-10 ratios, characteristic of a Th1 response, were increased in mice vaccinated with F3. The F1F3 chimera and the F3 vaccine reduced the parasite load in the liver.DiscussionThe F1F3 chimera, as described for the heterologous CL infections, also optimizes protection against the homologous visceral leishmaniasis infection by L. (L.) infantum chagasi, by a Th1 contribution from the F3 peptide and a regulatory response from the F1 peptide. Expression of the F1 and F3 domains in tandem induced higher efficacy than the simple mixture of the F1 and F3 domains.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1598755/fullLeishmania (L.) infantum chagasivisceral leishmaniasisnucleoside hydrolase NH36F1F3 recombinant chimeramixed or T-cell regulatory response
spellingShingle Daniele Crespo Gomes
Maria Paula Fonseca-Ribeiro
Marcus Vinicius Alves-Silva
Clarisa B. Palatnik-de-Sousa
The F1F3 recombinant chimera induced higher vaccine efficacy than its independent F1 and F3 components against Leishmania (L.) infantum chagasi mice infection
Frontiers in Immunology
Leishmania (L.) infantum chagasi
visceral leishmaniasis
nucleoside hydrolase NH36
F1F3 recombinant chimera
mixed or T-cell regulatory response
title The F1F3 recombinant chimera induced higher vaccine efficacy than its independent F1 and F3 components against Leishmania (L.) infantum chagasi mice infection
title_full The F1F3 recombinant chimera induced higher vaccine efficacy than its independent F1 and F3 components against Leishmania (L.) infantum chagasi mice infection
title_fullStr The F1F3 recombinant chimera induced higher vaccine efficacy than its independent F1 and F3 components against Leishmania (L.) infantum chagasi mice infection
title_full_unstemmed The F1F3 recombinant chimera induced higher vaccine efficacy than its independent F1 and F3 components against Leishmania (L.) infantum chagasi mice infection
title_short The F1F3 recombinant chimera induced higher vaccine efficacy than its independent F1 and F3 components against Leishmania (L.) infantum chagasi mice infection
title_sort f1f3 recombinant chimera induced higher vaccine efficacy than its independent f1 and f3 components against leishmania l infantum chagasi mice infection
topic Leishmania (L.) infantum chagasi
visceral leishmaniasis
nucleoside hydrolase NH36
F1F3 recombinant chimera
mixed or T-cell regulatory response
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1598755/full
work_keys_str_mv AT danielecrespogomes thef1f3recombinantchimerainducedhighervaccineefficacythanitsindependentf1andf3componentsagainstleishmanialinfantumchagasimiceinfection
AT mariapaulafonsecaribeiro thef1f3recombinantchimerainducedhighervaccineefficacythanitsindependentf1andf3componentsagainstleishmanialinfantumchagasimiceinfection
AT marcusviniciusalvessilva thef1f3recombinantchimerainducedhighervaccineefficacythanitsindependentf1andf3componentsagainstleishmanialinfantumchagasimiceinfection
AT clarisabpalatnikdesousa thef1f3recombinantchimerainducedhighervaccineefficacythanitsindependentf1andf3componentsagainstleishmanialinfantumchagasimiceinfection
AT danielecrespogomes f1f3recombinantchimerainducedhighervaccineefficacythanitsindependentf1andf3componentsagainstleishmanialinfantumchagasimiceinfection
AT mariapaulafonsecaribeiro f1f3recombinantchimerainducedhighervaccineefficacythanitsindependentf1andf3componentsagainstleishmanialinfantumchagasimiceinfection
AT marcusviniciusalvessilva f1f3recombinantchimerainducedhighervaccineefficacythanitsindependentf1andf3componentsagainstleishmanialinfantumchagasimiceinfection
AT clarisabpalatnikdesousa f1f3recombinantchimerainducedhighervaccineefficacythanitsindependentf1andf3componentsagainstleishmanialinfantumchagasimiceinfection